AM-201 for treatment or prevention of antipsychotic-induced weight gain and drowsiness

Came across this drug.

Auris Medical is developing AM-201, an intranasal formulation of betahistine, for the treatment or prevention of antipsychotic-induced weight gain and drowsiness / somnolence. Weight gain and associated metabolic problems such as impaired glucose tolerance and new-onset diabetes, hyperlipidemia, and cardiovascular disease and drowsiness are major side effects of drugs for schizophrenia and/or bipolar disorder.

http://aurismedical.com/product-candidates/am-201

3 Likes